Quick Answer
Fortress Biotech, Inc. reported Operating Income Loss of -$70.22 million for the year ending 2025.
- Fortress Biotech, Inc. showed an increase of +36.4% in Operating Income Loss from 2024 to 2025.
- This data is from Fortress Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$8.46 million | Q2 2013: -$10.29 million | Q3 2013: -$7.50 million | Q4 2013: -$9.52 million | Q1 2014: -$6.58 million | Q2 2014: -$4.76 million | Q3 2014: -$4.35 million | Q4 2014: -$4.96 million | Q1 2015: -$12.57 million | Q2 2015: -$7.76 million | Q3 2015: -$18.10 million | Q4 2015: -$12.96 million | Q1 2016: -$15.57 million | Q2 2016: -$17.04 million | Q3 2016: -$17.18 million | Q4 2016: -$32.22 million | Q1 2017: -$19.13 million | Q2 2017: -$25.50 million | Q3 2017: -$31.80 million | Q4 2017: -$30.62 million | Q1 2018: -$34.17 million | Q2 2018: -$25.40 million | Q3 2018: -$28.21 million | Q4 2018: -$41.21 million | Q1 2019: -$32.61 million | Q2 2019: -$25.29 million | Q3 2019: -$22.54 million | Q1 2020: -$21.53 million | Q2 2020: -$25.40 million | Q3 2020: -$23.04 million | Q1 2021: -$30.02 million | Q2 2021: -$42.86 million | Q3 2021: -$49.92 million | Q1 2022: -$47.27 million | Q2 2022: -$50.93 million | Q3 2022: -$50.73 million | Q1 2023: -$58.87 million | Q2 2023: -$50.11 million | Q3 2023: -$13.76 million | Q1 2024: -$36.57 million | Q2 2024: -$27.79 million | Q3 2024: -$22.10 million | Q1 2025: -$22.32 million | Q2 2025: -$36.47 million | Q3 2025: -$6.81 million.
- Over the full 17 years of available data (2009 to 2025), Fortress Biotech, Inc.'s Operating Income Loss has declined by 2,587.4%.
- Historical annual values: Fiscal year 2025: -$70.22 million | Fiscal year 2024: -$110.38 million | Fiscal year 2023: -$142.34 million | Fiscal year 2022: -$203.56 million | Fiscal year 2021: -$188.54 million | Fiscal year 2020: -$94.27 million | Fiscal year 2019: -$110.82 million | Fiscal year 2018: -$120.00 million | Fiscal year 2017: -$89.80 million | Fiscal year 2016: -$65.71 million | Fiscal year 2015: -$50.53 million | Fiscal year 2014: -$20.65 million | Fiscal year 2013: -$35.78 million | Fiscal year 2012: -$27.18 million | Fiscal year 2011: -$35.04 million | Fiscal year 2010: -$9.24 million | Fiscal year 2009: -$2.61 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: